Transcenta Holding Limited ("Transcenta") presented the progression-free survival (PFS) data from a Phase I/II study of Osemitamab (TST001) plus Capecitabine and Oxaliplatin (CAPOX) as the first-line treatment for advanced gastric/gastroesophageal junction (G/GEJ) cancer. The study showed that the addition of Osemitamab to chemotherapy provided benefit to patients with CLDN18.2 positive tumors, regardless of their expression levels. These findings support the upcoming global Phase III pivotal trial.
The study enrolled 64 patients with CLDN18.2 positive G/GEJ cancer, representing approximately 55% of all G/GEJ adenocarcinomas. The overall median PFS was 9.5 months, and there were no differences in PFS based on CLDN18.2 expression levels.
Osemitamab (TST001) is a high affinity humanized anti-CLDN18.2 monoclonal antibody that has shown potent anti-tumor activities in preclinical models